Serum GP88 as a predictive biomarker for hepatocellular carcinoma in patients with viral hepatitis C after direct-acting antiviral agents.

Author: EiichiTomita, IshidaHidekazu, MatsunamiHidetoshi, NaikiTakafumi, SaitoKuniaki, SerreroGinette, SuetsuguAtsushi, TakemuraMasao, TanakaTakuji, YamamotoYasuko

Paper Details 
Original Abstract of the Article :
Progranulin (GP88) is an 88-kDa glycoprotein growth factor with important biological effects in tumorigenesis and tumour survival. We investigated the usefulness of measuring serum GP88 concentrations as a predictive biomarker for hepatocellular carcinoma in patients with viral hepatitis C after tre...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1177/00045632211036723

データ提供:米国国立医学図書館(NLM)

GP88: A Potential Biomarker for Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC), a type of liver cancer, is a significant health concern. This study investigates the usefulness of serum GP88 concentrations as a predictive biomarker for HCC in patients with viral hepatitis C who have been treated with direct-acting antiviral agents.

GP88: A Potential Early Warning Sign

The study found that serum GP88 concentrations could potentially serve as a predictive biomarker for HCC in patients with viral hepatitis C. Higher levels of GP88 were associated with an increased risk of developing HCC, suggesting that measuring GP88 could help identify individuals at higher risk.

Liver Cancer: A Silent Threat

HCC is often diagnosed at a later stage, making early detection crucial for successful treatment. This study provides valuable insights into the potential role of GP88 as a predictive biomarker, potentially leading to earlier diagnosis and improved treatment outcomes. It's important to be aware of the risk factors for HCC and to discuss your concerns with your doctor.

Dr. Camel's Conclusion

This study, like a camel caravan seeking a clear path through the desert of liver disease, explores the potential of GP88 as a biomarker for HCC. GP88, like a guiding star, could help identify individuals at risk of developing this serious disease, allowing for early intervention and potentially improving treatment outcomes. It's a reminder that even in the challenging terrain of cancer, research continues to provide valuable insights and hope for patients.

Date :
  1. Date Completed 2022-01-13
  2. Date Revised 2022-01-13
Further Info :

Pubmed ID

34284614

DOI: Digital Object Identifier

10.1177/00045632211036723

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.